Prescription opioid misuse, abuse, and treatment in the United States: An update

American Journal of Psychiatry

Volumn 173, Issue 1, 2016, Pages 18-26

  Brady, Kathleen T ^a   McCauley, Jenna L ^a   Back, Sudie E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; NALOXONE; NALTREXONE; NARCOTIC ANALGESIC AGENT;

ANALGESIA; BEHAVIOR DISORDER ASSESSMENT; BEHAVIOR THERAPY; CHRONIC PAIN; COMPARATIVE EFFECTIVENESS; DEPRESSION; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG MISUSE; DRUG OVERDOSE; DRUG SURVEILLANCE PROGRAM; HEROIN DEPENDENCE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MEDICAL PRACTICE; MULTICENTER STUDY (TOPIC); OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PHYSIOTHERAPY; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCREENING TEST; UNITED STATES; ATTITUDE TO HEALTH; HEALTH CARE POLICY; NEEDS ASSESSMENT; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG MISUSE; PROCEDURES; SOCIAL PSYCHIATRY; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE;

HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH POLICY; HUMANS; NEEDS ASSESSMENT; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG MISUSE; PREVENTIVE PSYCHIATRY; SUBSTANCE ABUSE DETECTION; UNITED STATES;

EID: 84954305419     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.15020262     Document Type: Review

References (60)

1. Weissman DE, Haddox JD: Opioid pseudoaddiction: an iatrogenic syndrome. Pain 1989;36:363-366
2. McHugh RK, Nielsen S, Weiss RD: Prescription drug abuse: from epidemiology to public policy. J Subst Abuse Treat 2015;48:1-7
3. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality: The N-SSATS Report: Trends in the use of methadone and buprenorphine at substance abuse treatment facilities: 2003-2011. Rockville, Md, 2013
4. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality: Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings (NSDUH Series H-46, HHS Publication No (SMA) 13-4795). Rockville, Md, 2013
5. Calcaterra S, Glanz J, Binswanger IA: National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999-2009. Drug Alcohol Depend 2013;131:263-270
6. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality: Treatment Episode Data Set (TEDS), 2000-2012: National Admissions to Substance Abuse Treatment Services (DASIS Series S-61, HHS Publication No (SMA) 12-4701). Rockville, Md, 2014.
7. Department of Health and Human Services, Behavioral Health Coordinating Committee, Prescription Drug Abuse Subcommittee: Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities. http://www.cdc.gov/drugoverdose/pdf/hhs-prescription-drug-abuse-report-09.2013.pdf
8. Jones CM, Lurie P, Woodcock J: Addressing prescription opioid overdose: data support a comprehensive policy approach. JAMA 2014;312:1733-1734
9. Jann M, Kennedy WK, Lopez G: Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics. J Pharm Pract 2014;27:5-16
10. Bohnert AS, Ilgen MA, Trafton JA, et al: Trends and regional variation in opioid overdose mortality among Veterans Health Administration patients, fiscal year 2001 to 2009. Clin J Pain 2014;30:605-612
11. Sabzghabaee AM, Eizadi-Mood N, Yaraghi A, et al: Naloxone therapy in opioid overdose patients: intranasal or intravenous? A randomized clinical trial. Arch Med Sci 2014;10:309-314
12. Kerr D, Dietze P, Kelly AM: Intranasal naloxone for the treatment of suspected heroin overdose. Addiction 2008;103:379-386
13. Clark AK, Wilder CM, Winstanley EL: A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med 2014;8:153-163
14. Veilleux JC, Colvin PJ, Anderson J, et al: A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010;30:155-166
15. Zacharoff KL, McCarberg BH, Reisner L, et al: Managing Chronic Pain With Opioids in Primary Care, 2nd ed. Newton, Mass, Inflexxion, 2010
16. Fishman SM: Responsible Opioid Prescribing: A Clinician's Guide, 2nd ed. Washington, DC, Waterford Life Sciences, 2012
17. Nuckols TK, Anderson L, Popescu I, et al: Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med 2014;160:38-47
18. Executive Office of the President of the United States, Office of National Control Policy: Epidemic: Responding to America's Prescription Drug Abuse Crisis. Washington, DC, 2011. https://www.whitehouse.gov/sites/default/files/ondcp/issues-content/prescriptiondrugs/rx-abuse-plan-0.pdf
19. National Conference of State Legislatures: Prevention of Prescription Drug Overdose and Abuse. Washington, DC, July 28, 2014. http://www.ncsl.org/research/health/prevention-of-prescriptiondrugovrdose-and-abuse.aspx
20. Kuehn BM: CDC: Major disparities in opioid prescribing among states: some states crack down on excess prescribing. JAMA 2014;312:684-686
21. Prescription Drug Monitoring Program (PDMP) Center of Excellence: Briefing on PDMP. Waltham, Mass, Brandeis University, April 2013
22. Barclay JS, Owens JE, Blackhall LJ: Screening for substance abuse risk in cancer patients using the Opioid Risk Tool and urine drug screen. Support Care Cancer 2014;22:1883-1888
23. Back SE, Payne RL, Simpson AN, et al: Gender and prescription opioids: findings from the National Survey on Drug Use and Health. Addict Behav 2010;35:1001-1007
24. Passik SD, Kirsh KL, Casper D: Addiction-related assessment tools and pain management: instruments for screening, treatment planning, and monitoring compliance. Pain Med 2008;9(suppl S2):S145-S166
25. Webster LR, Webster RM: Predicting aberrant behaviors in opioidtreated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005;6:432-442
26. Saunders JB, Aasland OG, Babor TF, et al: Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons With Harmful Alcohol Consumption-II. Addiction 1993;88:791-804
27. Humeniuk R, Ali R, Babor TF, et al: Validation of the Alcohol, Smoking, And Substance Involvement Screening Test (ASSIST). Addiction 2008;103:1039-1047
28. Gavin DR, Ross HE, Skinner HA: Diagnostic validity of the drug abuse screening test in the assessment of DSM-III drug disorders. Br J Addict 1989;84:301-307
29. Grant BF, Hasin DS: The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS). Rockville, Md, National Institute on Alcohol Abuse and Alcoholism, 1992
30. Robins LN: Diagnostic grammar and assessment: translating criteria into questions, in The Validity of Diagnosis. Edited by Robins LN, Barrett J. New York, Raven Press, 1989, pp 263-278
31. First MB, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for DSM-IV Axis I Disorders, Clinical Version (SCID-CV). Washington, DC, American Psychiatric Press, 2002
32. Sheehan DV, Lecrubier Y, Sheehan KH, et al: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33
33. Butler SF, Budman SH, Fanciullo GJ, et al: Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy. Clin J Pain 2010;26:770-776
34. McLellan AT, Kushner H, Metzger D, et al: The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992;9:199-213
35. Sobell LC, Sobell MB: Timeline follow-back: a technique for assessing self-reported ethanol consumption, in Measuring Alcohol Consumption: Psychosocial and Biological Methods. Edited by Litten RZ, Allen J. Totowa, NJ, Humana Press, 1992, pp 41-72
36. Holmes D: Prescription drug addiction: the treatment challenge. Lancet 2012;379:17-18
37. Mattick RP, Breen C, Kimber J, et al: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014;2:CD002207
38. Brady KT, McCauley JL, Back SE: Opiate misuse and dependence, in Clinical Textbook of Addictive Disorders, 4th ed. Edited by Mack AH, Brady KT, Miller SI, Frances RJ. New York, Guilford, 2014
39. Amato L, Minozzi S, Davoli M, et al: Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2011; (9): CD005031
40. World Health Organization: Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva, 2009
41. Bell J, Trinh L, Butler B, et al: Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009;104:1193-1200
42. Ling W, Charuvastra C, Collins JF, et al: Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998;93:475-486
43. Sigmon SC, Bisaga A, Nunes EV, et al: Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse 2012;38:187-199
44. Sullivan MA, Bisaga A, Mariani JJ, et al: Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade? Drug Alcohol Depend 2013;133:80-85
45. Gibson AE, Degenhardt LJ: Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug Alcohol Rev 2007;26:405-410
46. Potter JS, Marino EN, Hillhouse MP, et al: Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from Starting Treatment With Agonist Replacement Therapies (START). J Stud Alcohol Drugs 2013;74:605-613
47. Sigmon SC, Dunn KE, Saulsgiver K, et al: Arandomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry 2013;70:1347-1354
48. Sigmon SC: The untapped potential of office-based buprenorphine treatment. JAMA Psychiatry 2015;72:395-396
49. Fiellin DA, Schottenfeld RS, Cutter CJ, et al: Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med 2014;174:1947-1954
50. Weiss RD, Potter JS, Fiellin DA, et al: Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011;68:1238-1246
51. McDermott KA, Griffin ML, Connery HS, et al: Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population. J Clin Psychiatry 2015;76:189-194
52. Northrup TF, Stotts AL, Green C, et al: Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model. Addict Behav 2015;41:20-28
53. Potter JS, Dreifuss JA, Marino EN, et al: The multi-site prescription opioid addiction treatment study: 18-month outcomes. J Subst Abuse Treat 2015;48:62-69
54. Weiss RD, Potter JS, Griffin ML, et al: Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend 2015;150:112-119
55. Jones HE, Kaltenbach K, Heil SH, et al: Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363:2320-2331
56. Prendergast M, Podus D, Finney J, et al: Contingency management for treatment of substance use disorders: a meta-analysis. Addiction 2006;101:1546-1560
57. Weiss RD, Griffin ML, Potter JS, et al: Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management? Drug Alcohol Depend 2014;140:118-122
58. Bogstrand ST, Normann PT, Rossow I, et al: Prevalence of alcohol and other substances of abuse among injured patients in a Norwegian emergency department. Drug Alcohol Depend 2011;117:132-138
59. Gardner EL: Pain management and the so-called "risk" of addiction: a neurobiological perspective, in Pain and Chemical Dependency. Edited by Smith PS. New York, Oxford University Press, 2008, pp 427-435
60. Dart RC, Surratt HL, Cicero TJ, et al: Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015;372:241-248